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The June, 2004 meeting of the IHPBA inWashington,
D.C. provided an excellent opportunity for liver
transplant and HPB surgeons and other liver-focused
specialists to exchange important ideas regarding the
current status and future directions in surgery.
Presented papers could mostly be divided into one of
5 broad overlapping categories: liver transplantation,
treatment strategies for hepatocellular carcinoma
(HCC), management of non-HCC liver tumors,
hepatic protection in liver surgery, and new technology
in liver-related surgery. In addition, video sessions
covering each of these areas facilitated the sharing of
procedural approaches and were an important and
popular feature of the meeting.
Topics associated with liver transplantation were
heavily focused on live donor liver transplantation,
organ allocation, and recent developments impacting
transplantation for HCC. There has been an overall
decline in the use of live donor transplantation for
adults in many regions of the world since 2002, but
there appears to be renewed interest in this procedure.
Donor-associated morbidity is receiving increasing
scrutiny and changing algorithms for organ allocation
(including the MELD system) are influencing con-
sideration for live donor transplantation. The impor-
tance of waiting-times are being minimized with more
attention on accurate disease-specific assessment to
minimize recipient deaths while patients are wait-
listed. The listing priority assigned to liver tumor
patients remains an area of controversy inmany regions
of the world and increasing attention is being focused
on the use of patient drop-out rates (by tumor stage) to
assist in assigning priority. There is now a generalized
recognition that transplantation of the highest acuity
patients first leads to greater resource use and slightly
worse results for the highest disease severity, but
this appears to be the prevailing system in use in
many regions of the world. There are continued
investigations of liver support devices and auxiliary
transplantation, but these have yet to advance to
routine clinical care.
An important observation during the meeting was
the differing approaches regarding liver transplantation
that appear to be undertaken in different regions of
world based on cultural, access, and economic factors.
For example, regions where there is no uniform
standard for brain death declaration have either very
low rates of transplantation, or have much greater use
of live donor transplantation and/or use of non-
heartbeating donors. Local and regional influence also
seems to play a major role in decisions regarding
management of HCC, particularly in Child’s A and B
cirrhotic patients. For example, patients in Asian
countries appear to be much for likely to undergo
resection for HCC, whereas transplantation appears to
be more heavily favored in the U.S. and other Western
countries. Data presented suggested that resection
followed by salvage transplantation in those with
recurrences in the remnant liver may be comparable
to primary OLT, however this remains an area of
controversy. Additional data (clinical trials) presented
at future IHPBA meetings should clarify this issue and
may allow modification of organ allocation for such
patients.
The role of adjuvant and neoadjuvant therapy for
HCC remains unproven, with no evidence to support
use of systemic therapy prior to, or following, liver
resection or transplantation. Hepatic-directed therapy
appears to be a useful adjunct for HCC, particularly
transarterial chemoembolization (TACE) and ablative
therapy, and recent preliminary studies suggest
encouraging results with transarterial radiotherapy.
The use of neoadjuvant therapy prior to transplan-
tation is being increasingly utilized for prevention of
tumor progression for listed patients, but there is no
proven benefit to this approach and studies in this area
are lacking. TACE and tumor ablation can lead to
tumor down-staging for patients exceeding listing
criteria (allowing for subsequent OLT), but outcomes
for these patients appear to be worse than for patients
with earlier stage disease.
The treatment of colorectal metastases to the liver
represents one of the better defined and more mature
aspects of HPB surgery, where the role of surgery
is now well-defined. Improvements in imaging tech-
nology, including the routine use of PET scanning for
tumor staging at some centers, appears to facilitate
improved patient selection and significantly improved
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long-term results. In addition, improvements in
systemic and regional chemotherapy have allowed
tumor down-staging which has resulted in conversion
of unresectable to resectable hepatic tumors in up to
15% of patients in some reports.
Several features of cholangiocarcinoma manage-
ment emerged during the meeting including the
improved tumor detection that has resulted from
advances in non-invasive imaging; the need for invasive
imaging studies including angiography has diminished
markedly worldwide. Almost all centers now report
that achieving margin-negative resection almost always
requires concomitant major liver resection. There
appears to be an increasing use of selective preoperative
portal vein embolization for hepatic protection to
lessen the risk of post-resection liver failure related to
small liver remnant volumes. Additional studies are
needed to clarify the role of adjuvant therapy for this
malignancy.
Developments in new technology were a major focus
of theWashington IHPBAmeeting. The increasing use
of laparoscopy for standard liver resection, for live
donor liver surgery, and to facilitate ablative therapy
and hepatic artery infusion pump placement were all
highlighted. Several groups reported on the use of the
daVinci robotic device to facilitate hepatic resection.
Another area receiving much attention was the
enhanced use of imaging in liver surgery, specifically
for pre-operative virtual planning in liver resection
(including teaching of surgical skills), and new imaging
software available for 3-D imaging. While not yet
available for routine clinical use, the development of
instrument tracking and image-guidance during liver
resection should occur over the next 5-years. New
developments in transectional techniques have been
recently introduced including the water-jet dissector,
the use of radiofrequency resection, and saline-linked
surface coagulators, among others. New approaches
for use of microwave therapy for liver tumor ablation
were presented, with suggestions that this technology
may result in larger, more uniform ablation zones and
shorter ablation times. The role of tumor ablation,
however, remains unresolved and no prospective or
case-controlled trials have been reported in patients
with resectable tumors to establish the appropriate
place for this therapy.
A special session at theWashington meeting focused
on outcomes in liver surgery including the need for
evidence-based medicine in liver surgery. Significant
variation in liver surgery exists worldwide depending
on many factors including whether liver surgery is
regionalized and local incentives for care. There
appears to be great international interest in improving
training in transplant and HPB surgery. Subspecialty
training remains variable with experience often occur-
ring as part of Surgical Oncology/HPB training, Liver
Transplant/HPB training, or as part of GI/Laparo-
scopy/HPB training; it remains unclear whether sub-
specialty training will become recognized at National
Board levels. What does seem clear is that the casual or
occasional performance of HPB surgery is no longer
suitable and that experience in HPB/Transplant
Surgery appears to correlate closely with improved
patient outcomes.
Finally, one of the most well received and popular
features of the meeting involved the video sessions. A
common feature of many presented videos included
concomitant vascular reconstruction to extend or
improve results of liver resection or transplantation.
A significant percentage of videos also focused on
developing laparoscopic and minimally invasive tech-
niques for major liver cases.
Based on the 2004 IHPBA meeting in Washington,
DC, the IHPBA will continue to play a vital role in
future liver surgery by providing an international forum
for surgeons interested in HPB and liver transplant
surgery. This forum with allow internationally promi-
nent liver surgeons to present and discuss regional
influences and differing approaches including such
topics as organ allocation priorities, management
strategies for HCC, novel use of imaging during liver
surgery, the enhanced use of minimally invasive
surgery, and the development of new technology in
liver-related surgery. In this way the IHPBA should
remain the leading international force in liver surgery
for the foreseeable future.
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